NCT05460624

Brief Summary

The purpose of this study is to test the effects of provisioning twelve eggs weekly, incorporated into breakfast meals, on composite scores of executive functioning and memory using the CNSVS computerized test platform in older adults in a randomized study.

Trial Health

30
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Timeline
Completed

Started Feb 2023

Geographic Reach
1 country

1 active site

Status
withdrawn

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

July 12, 2022

Completed
3 days until next milestone

First Posted

Study publicly available on registry

July 15, 2022

Completed
7 months until next milestone

Study Start

First participant enrolled

February 10, 2023

Completed
Same day until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 10, 2023

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

February 10, 2023

Completed
Last Updated

February 28, 2023

Status Verified

February 1, 2023

Enrollment Period

Same day

First QC Date

July 12, 2022

Last Update Submit

February 24, 2023

Conditions

Outcome Measures

Primary Outcomes (2)

  • Composite Memory

    Derived from the CNSVS verbal and visual memory test scores

    12-week

  • Executive Function

    Derived from Shifting Attention Test (SAT) from CNSVS battery of tests

    12-week

Secondary Outcomes (7)

  • Verbal memory

    12-week

  • Visual memory

    12-week

  • Processing speed

    12-week

  • Reaction time

    12-week

  • Simple Attention

    12-week

  • +2 more secondary outcomes

Other Outcomes (10)

  • Dietary intakes

    12-week

  • Physical performance

    12-week

  • Serum total cholesterol

    12-week

  • +7 more other outcomes

Study Arms (2)

Intervention group

EXPERIMENTAL

Participants randomized to the intervention group will receive six premade egg-containing breakfast meals per week in the form of a 3-day rotating menu. Each meal contains 2 eggs to provide 12 eggs per week for a duration of 12 weeks.

Other: Egg-containing breakfast

Control group

OTHER

Participants randomized to the control group will receive breakfast meals in the form of a 3-day rotating menu including typical foods found in American diets excluding eggs, e.g., corn flakes, milk, sausage, granola bars, fruit. Control recipes are matched to the intervention foods on total energy and saturated fat and to the 'What We Eat in America' on percent energy from macronutrients.

Other: Typical American-style breakfast excluding eggs

Interventions

Involves participants eating six premade egg-containing breakfast meals per week for 12 weeks. Each meal contains 2 eggs to provide 12 eggs per week.

Intervention group

Involves participants eating six premade egg-excluding breakfast meals per week for 12 weeks. Breakfast meals are matched to the intervention egg-containing breakfast meals on total energy and saturated fat and to the 'What We Eat in America' on percent energy from macronutrients.

Control group

Eligibility Criteria

Age65 Years - 90 Years
Sexall
Healthy VolunteersYes
Age GroupsOlder Adult (65+)

You may qualify if:

  • Participant has autonomy over their food choices.
  • Participant has the common appliances for storing refrigerated and frozen foods (i.e., refrigerator and freezer).
  • Participant has common appliances to defrost/prepare foods (e.g., microwave oven, oven, stove, etc.).
  • Participant has sufficient corrected visual acuity to read simple instructions on a computer/laptop screen
  • Participant has a CNSVS standard (age-matched) score of 85-105 (inclusive) for either the domain composite memory (raw score is the sum of verbal memory score and visual memory score) or the domain executive function, and 80-110 for the other.
  • Participant has no plans to change their routine (physical activity pattern, dietary habits, sleep pattern, smoking habits) during the study period unless advised as part of study participation.
  • Participant is willing to follow screening/assessment visit instructions.
  • Participant is willing to consume the study foods as provided at the breakfast meals during the study period.
  • Participant is willing and able to visit IUB campus on specified in-person visit days.
  • Participant understands the study procedures and signs the informed consent to participate in the study and is willing to complete study procedures.

You may not qualify if:

  • Participant is not fully vaccinated for COVID-19.
  • Participant reports habitually consuming greater than 5.5 eggs per week.
  • Participant has sensitivity, allergy, taste aversion, or other aversion (e.g., vegan) to any ingredient of the study food.
  • Participant has substantial dietary restrictions (e.g., chronic kidney disease or familial hypercholesterolemia diet) that, based on the judgment of the Principal Investigator, would interfere with the intervention.
  • Participant is under active chemotherapy treatment.
  • Participant is participating in a parallel research study that, based on the judgment of the Principal Investigator, would interfere with his or her ability to comply with the study protocol, or which might confound the interpretation of the study results.
  • Participant is not able to read.
  • Participant reports current use of cognitive enhancing medications, attention/concentration enhancing medications, anticonvulsant medications, and mood stabilizing medications.
  • Participant has a condition that, based on the judgment of the Principal Investigator, would interfere with his or her ability to provide informed consent or comply with the study protocol, or which might confound the interpretation of the study results or put the person at undue risk.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Indiana University-Bloomington

Bloomington, Indiana, 47401, United States

Location

Study Officials

  • Andrew W Brown, PhD

    Indiana University, Bloomington

    PRINCIPAL INVESTIGATOR
0

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Masking Details
Outcome assessments will be conducted before randomization at baseline and by individuals blinded to the treatment assignments at follow-up. Data will be analyzed prior to unblinding.
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assistant Professor

Study Record Dates

First Submitted

July 12, 2022

First Posted

July 15, 2022

Study Start

February 10, 2023

Primary Completion

February 10, 2023

Study Completion

February 10, 2023

Last Updated

February 28, 2023

Record last verified: 2023-02

Data Sharing

IPD Sharing
Will share

All deidentified data and statistical code used for publication of the study results will be accessible publicly for other researchers to be able to reproduce and/or verify published results after confirmation that deidentified data cannot be reasonably statistically re-identified.

Shared Documents
STUDY PROTOCOL, SAP, ANALYTIC CODE
Time Frame
Immediately
Access Criteria
Publicly available to anyone for the purpose of reproducing and/or verifying published results.

Locations